0001213900-23-083869.txt : 20231106 0001213900-23-083869.hdr.sgml : 20231106 20231106160322 ACCESSION NUMBER: 0001213900-23-083869 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231106 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231106 DATE AS OF CHANGE: 20231106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Augmedix, Inc. CENTRAL INDEX KEY: 0001769804 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 833299164 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40890 FILM NUMBER: 231379917 BUSINESS ADDRESS: STREET 1: 111 SUTTER STREET, SUITE 1300 CITY: SAN FRANCISC STATE: CA ZIP: 94104 BUSINESS PHONE: 561-989-2208 MAIL ADDRESS: STREET 1: 111 SUTTER STREET, SUITE 1300 CITY: SAN FRANCISC STATE: CA ZIP: 94104 FORMER COMPANY: FORMER CONFORMED NAME: Malo Holdings Corp DATE OF NAME CHANGE: 20190305 8-K 1 ea187794-8k_augmedix.htm CURRENT REPORT
0001769804 false 0001769804 2023-11-06 2023-11-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): November 6, 2023

 

 

 

AUGMEDIX, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-40890   83-3299164

(State or other jurisdiction
of incorporation)

  

(Commission File Number)

  

(I.R.S. Employer
Identification No.)

 

111 Sutter Street, Suite 1300, San Francisco, California 94104

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (888) 669-4885

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value per share   AUGX   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On November 6, 2023, Augmedix, Inc., a Delaware corporation (the “Company”), released its financial results for the third quarter ended September 30, 2023. The press release announcing the release of financial results is furnished as Exhibit 99.1 and is incorporated herein by reference.

 

The information provided in this Item 2.02, including Exhibit 99.1, is intended to be “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press release dated November 6, 2023 announcing third quarter 2023 financial results.
     
104   Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AUGMEDIX, INC.
     
Dated: November 6, 2023 By: /s/ Paul Ginocchio
    Paul Ginocchio
    Chief Financial Officer

 

 

2

 

 EX-99.1 2 ea187794ex99-1_augmedix.htm PRESS RELEASE DATED NOVEMBER 6, 2023 ANNOUNCING THIRD QUARTER 2023 FINANCIAL RESULTS

Exhibit 99.1

 

 

Augmedix Delivers 50% Revenue Growth and Expanded Gross Margins for Third Quarter of 2023

 

SAN FRANCISCO, November 6, 2023 – Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading ambient medical documentation and data solutions, reported today financial results for the three and nine months ended September 30, 2023.

 

“The third quarter marked another period of strong progress for Augmedix as we continue to be a leader in the large and rapidly growing ambient medical documentation market,” commented Manny Krakaris, Chief Executive Officer at Augmedix. “Growing adoption of Augmedix Live and Augmedix Notes drove 50% revenue growth and net revenue retention of 157%, while expanding gross margins by 390 basis points to 49.5%. With strong revenue growth and improving profitability, we are on track to achieve our financial goals and are increasing our revenue guidance for 2023 accordingly.”

 

Continued Mr. Krakaris, “We are delivering strong financial results while expanding our product portfolio and building out the foundations of our data and platform strategies. We recently launched early access to Augmedix Go, our fully automated scalable AI medical documentation solution, and we continue to collaborate closely with HCA Healthcare to launch Augmedix Go for the emergency room setting. We have also forged strategic relationships with three innovative digital health companies as part of our open network and platform strategy. These vendor partners will be able to use our delivery platform through application programming interfaces (APIs) so that they and our health system partners can efficiently benefit and generate incremental ROI from our structured data and bi-directional communication channel to the point of care.”

 

“It is clearer than ever that there is a tremendous opportunity in front of Augmedix,” concluded Mr. Krakaris. “As healthcare systems lean into our ambient medical documentation technology to reduce the burden on clinicians and enhance operating efficiency, they are increasingly looking to leverage our structured data for insights and our bi-directional communication channel to deliver vital information that can effectuate change at the point of care. We are confident that addressing these expanded upstream and downstream requirements will create greater value for our customers and ultimately, our shareholders.”

 

Third Quarter 2023 Financial and Business Highlights

 

All comparisons, unless otherwise noted, are to the three months ended September 30, 2022.

 

●Total revenue was $11.8 million, an increase of 50% compared to $7.9 million.

 

●Dollar-based Net Revenue Retention was 157% for Health Enterprise customers compared to 130% in the third quarter of 2022 and 148% in the second quarter of 2023.

 

●Average Clinicians in Service grew 47%.

 

●GAAP Gross Margin increased 390 basis points to 49.5% compared to 45.7%.

 

 

 

 

●GAAP Operating Expenses were $10.2 million, compared to $9.0 million in the third quarter of 2022 and $10.0 million in the second quarter of 2023.

 

●GAAP Net Loss narrowed to $4.4 million compared to $5.5 million.

 

●EBITDA losses declined to $3.7 million compared to $5.0 million. Adjusted EBITDA losses declined to $3.1 million compared to $4.5 million, which excludes stock-based compensation in both periods. Adjusted EBITDA losses again declined sequentially from $3.6 million in the second quarter of 2023.

 

●Cash, cash equivalents, and restricted cash were $22.3 million as of September 30, 2023, compared to $22.0 million as of December 31, 2022.

 

●The interest only period on our $20 million term loan with SVB was lengthened from January 2024 to July 2024 as we exceeded the financial requirements for extension during the third quarter.

 

●Launched the early access release of Augmedix Go for the clinical setting, a clinician-controlled mobile app that uses generative AI to create a fully automated draft medical note instantaneously.

 

●Established strategic collaborations with three innovative digital health companies – Myndshft, Ellipsis Health, and The Sullivan Group – to enhance healthcare enterprise efficiency and patient outcomes.

 

●Hosted the initial AI Advisory Council meeting with distinguished academics, governance experts, and customers to provide strategic guidance on Augmedix’s product roadmap on the development and use of AI.

 

●Enhanced collaboration with HCA Healthcare and Google Cloud to bring generative AI to hospitals.

 

●Achieved certified status by HITRUST for information security, which validates Augmedix’s commitment to safeguarding sensitive patient information data.

 

Non-GAAP operating expenses, EBITDA and Adjusted EBITDA are a Non-GAAP financial measure. Please see “Non-GAAP Financial Measures” below and the Reconciliation of the GAAP to Non-GAAP Financial Measures table below.

 

2023 Revenue Guidance

 

Augmedix now expects approximately $44.5 million of revenue in 2023.

 

Conference Call

 

Augmedix will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on Monday, November 6, 2023, to discuss its third quarter 2023 financial results. The conference call can be accessed by dialing +1-877-407-3982 for U.S. participants or +1-201-493-6780 for international participants and referencing conference ID #13741543. Interested parties may access a live and archived webcast of the event on the “Investor Relations” section of the Company’s website at: ir.augmedix.com.

 

2

 

 

Definition of Key Metrics

 

Dollar-Based Net Revenue Retention: We define a “Health Enterprise” as a company or network of doctors that has at least 50 clinicians currently employed or affiliated that could utilize our services. Dollar-based net revenue retention is determined as the revenue from Health Enterprises as of twelve months prior to such period end as compared to revenue from these same Health Enterprises as of the current period end, or current period revenue. Current period revenue includes any expansion or new products and is net of contraction or churn over the trailing twelve months but excludes revenue from new Health Enterprises in the current period. We believe growth in dollar-based net revenue retention is a key indicator of the performance of our business as it demonstrates our ability to increase revenue across our existing customer base through expansion of users and products, as well as our ability to retain existing customers.

 

Clinicians in Service: We define a clinician in service as an individual doctor, nurse practitioner or other healthcare professional using our services. We average the month-end number of clinicians in service for all months in the measurement period and the number of clinicians in service at the end of the month immediately preceding the measurement period. We believe growth in the number of clinicians in service is an indicator of the performance of our business as it demonstrates our ability to penetrate the market and grow our business.

 

About Augmedix

 

Augmedix (Nasdaq: AUGX) delivers industry-leading, ambient medical documentation and data solutions to healthcare systems, physician practices, hospitals, and telemedicine practitioners.

 

Augmedix is on a mission to help clinicians and patients form a human connection by seamlessly integrating our technology at the point of care. Augmedix’s proprietary platform digitizes natural clinician-patient conversations, which are converted into comprehensive medical notes and structured data in real time. The company’s platform uses automatic speech recognition, and natural language processing, including large language models, to generate accurate and timely medical notes that are transferred into the EHR.

 

Augmedix’s products relieve clinicians of administrative burden, in turn, reducing burnout, increasing clinician efficiency and improving patient access. Through Augmedix’s proprietary platform and bi-directional communication channel, Augmedix is ideally suited to serve as the vehicle for change at the point of care.

 

Augmedix is headquartered in San Francisco, CA, with offices around the world. To learn more, visit www.augmedix.com.

 

3

 

 

Contact Information

 

Investors:

 

Matt Chesler, CFA

FNK IR

(646) 809-2183

augx@fnkir.com

investors@augmedix.com

 

Media:

 

Kaila Grafeman

Augmedix

pr@augmedix.com

 

Non-GAAP Financial Measures

 

To supplement our consolidated financial statements, which are prepared and presented in accordance with GAAP, we use the following non-GAAP financial measures: Non-GAAP gross profit, Non-GAAP gross margin, Non-GAAP Operating Expenses, EBITDA, and adjusted EBITDA. The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.

 

We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our recurring core business operating results. We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. These non-GAAP financial measures also facilitate management’s internal comparisons to our historical performance and liquidity as well as comparisons to our competitors’ operating results. We believe these non-GAAP financial measures are useful to investors both because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by our institutional investors and the analyst community to help them analyze the health of our business.

 

There are a number of limitations related to the use of non-GAAP financial measures. We compensate for these limitations by providing specific information regarding the GAAP amounts excluded from these non-GAAP financial measures and evaluating these non-GAAP financial measures together with their relevant financial measures in accordance with GAAP.

 

For more information on the non-GAAP financial measures, please see the Reconciliation of GAAP to non-GAAP Financial Measures table in this press release. This accompanying table includes details on the GAAP financial measures that are most directly comparable to Non-GAAP financial measures and the related reconciliations between these financial measures.

 

4

 

 

Forward-Looking Statements

 

This press release contains “forward-looking statements” that involve a number of risks and uncertainties. Words such as “believes,” “may,” “will,” “estimates,” “potential,” “continues,” “anticipates,” “intends,” “expects,” “could,” “would,” “projects,” “plans,” “targets,” “excited,” “optimistic,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the Company’s expectations regarding revenues for the full fiscal year 2023 and the achievement of its financial goals; the ability of the Company’s vendor and health system partners to efficiently benefit from, and generate incremental ROI through the use of, the Company’s structured data and bi-directional communication channel to the point of care; the tremendous opportunity in front of Augmedix; healthcare systems leaning into the Company’s ambient medical documentation technology to reduce the burden on clinicians and enhance operating efficiency; the increase in healthcare systems looking to leverage the Company’s structured data for insights and the Company’s bi-directional communication channel to deliver vital information that can effectuate change at the point of care; and the Company’s confidence that addressing these expanded upstream and downstream requirements will lead to greater value for its customers and ultimately its shareholders. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in our most recent Form 10-K filed with the Securities and Exchange Commission on April 17, 2023 as well as other documents that may be filed by us from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: our expectations regarding changes in regulatory requirements; our ability to interoperate with the electronic health record systems of our customers; our reliance on vendors; our ability to attract and retain key personnel; the competition to attract and retain remote documentation specialists; anticipated trends, growth rates, and challenges in our business and in the markets in which we operate; our ability to further penetrate our existing customer base; our ability to protect and enforce our intellectual property protection and the scope and duration of such protection; developments and projections relating to our competitors and our industry, including competing dictation software providers, third-party, non-real time medical note generators and real time medical note documentation services; and the impact of current and future laws and regulations. Past performance is not necessarily indicative of future results. The forward-looking statements included in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

 

5

 

 

AUGMEDIX, INC.

Condensed Consolidated Statements of Operations

(Unaudited, in thousands except EPS and Average Clinicians in Service)

 

   Three Months Ended 
   September 30, 
   (unaudited) 
   2023   2022 
Revenue  $11,767   $7,864 
Cost of revenue   5,937    4,274 
Gross profit   5,830    3,590 
Operating Expenses            
General and administrative   4,568    4,136 
Sales and marketing   2,729    2,304 
Research and development   2,936    2,608 
Total operating expenses   10,233    9,048 
Loss from operations   (4,403)   (5,458)
             
Other income (expense), net   (4)   (32)
Net loss  $(4,407)  $(5,490)
           
Weighted average common stock outstanding   45,521    37,427 
           
Earnings Per Share  $(0.10)  $(0.15)
           
Average Clinicians in Service (CIS)   1,650    1,121 

 

6

 

 

AUGMEDIX, INC. 

Condensed Consolidated Balance Sheet 

(Unaudited, in thousands) 

 

   September 30,   December 31, 
   2023   2022 
Assets    
Cash, cash equivalents, and restricted cash  $22,286   $21,988 
Accounts receivables, net   9,446    6,354 
Other assets   9,101    5,299 
Total assets   40,833    33,641 
             
Liabilities & Stockholders’ Equity            
Liabilities            
Accounts payable  $1,816   $1,563 
Deferred revenue   7,993    7,254 
Loan payable   20,108    15,134 
Other liabilities   10,182    8,224 
Total liabilities  $40,099   $32,175 
Stockholders’ equity  $734   $1,466 
Total liabilities & stockholders’ equity  $40,833   $33,641 

 

7

 

 

AUGMEDIX, INC. 

Condensed Consolidated Statement of Cash Flows 

(Unaudited, in thousands) 

 

 

   Nine Months Ended 
   September 30, 
   2023   2022 
Cash flows from operating activities  $(14,468)  $(12,387)
Cash flows from investing activities   (1,912)   (816)
Cash flows from financing activities   16,989    (1,244)
Effect of exchange rate changes on cash and restricted cash   (311)   (143)
Net decrease in cash  $298   $(14,590)
Cash, restricted cash, and cash equivalents at the beginning of the period  $21,988   $41,587 
Cash, restricted cash, and cash equivalents at the end of the period  $22,286   $26,997 

 

8

 

 

AUGMEDIX, INC. 

Reconciliation of GAAP to Non-GAAP Financial Measures 

(Unaudited, in thousands) 

 

   Three Months Ended 
   September 30, 
   (unaudited) 
  2023   2022 
Stock Based Compensation Expense        
Cost of revenue  $33   $22 
General and administrative   425    320 
Sales and marketing   57    50 
Research and development   122    85 
Total stock-based compensation expense  $637   $477 
             
Net loss  $(4,407)  $(5,490)
Interest   355    257 
Tax   84    19 
Depreciation   252    217 
EBITDA  $(3,716)  $(4,997)
Add: Stock-based compensation   637    477 
Adjusted EBITDA  $(3,079)  $(4,520)
             
GAAP Cost of revenue  $5,937   $4,274 
Less: Stock-based compensation   33    22 
Non-GAAP cost of revenue  $5,904   $4,252 
           
Non-GAAP Gross Profit  $5,863   $3,612 
Non-GAAP Gross Margin   49.8%   45.9%
             
GAAP Operating expenses  $10,233   $9,048 
Less: Stock-based compensation   604    455 
Non-GAAP operating expenses  $9,629   $8,593 

 

 

9

 

 

 

 

 

 GRAPHIC 3 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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end EX-101.SCH 4 augx-20231106.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 augx-20231106_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 augx-20231106_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 06, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 06, 2023
Entity File Number 001-40890
Entity Registrant Name AUGMEDIX, INC.
Entity Central Index Key 0001769804
Entity Tax Identification Number 83-3299164
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 111 Sutter Street
Entity Address, Address Line Two Suite 1300
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94104
City Area Code 888
Local Phone Number 669-4885
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol AUGX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false

XML 8 ea187794-8k_augmedix_htm.xml IDEA: XBRL DOCUMENT 0001769804 2023-11-06 2023-11-06 iso4217:USD shares iso4217:USD shares 0001769804 false 8-K 2023-11-06 AUGMEDIX, INC. DE 001-40890 83-3299164 111 Sutter Street Suite 1300 San Francisco CA 94104 888 669-4885 false false false false Common Stock, $0.0001 par value per share AUGX NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://augmedix.com/role/Cover Cover Cover 1 false false All Reports Book All Reports augx-20231106.xsd augx-20231106_lab.xml augx-20231106_pre.xml ea187794-8k_augmedix.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea187794-8k_augmedix.htm": { "nsprefix": "AUGX", "nsuri": "http://augmedix.com/20231106", "dts": { "schema": { "local": [ "augx-20231106.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "augx-20231106_lab.xml" ] }, "presentationLink": { "local": [ "augx-20231106_pre.xml" ] }, "inline": { "local": [ "ea187794-8k_augmedix.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://augmedix.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea187794-8k_augmedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea187794-8k_augmedix.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001213900-23-083869-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-083869-xbrl.zip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end